Literature DB >> 163087

Cyclic AMP and cyclic GMP content and binding in malignancy.

M L Goldberg, G C Burke, H P Morris.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 163087     DOI： 10.1016/s0006-291x(75)80141-0

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN： 0006-291X            Impact factor:   3.575


× No keyword cloud information.
  7 in total

1.  Effect of buffer composition on binding of adenosine 3':5'-cyclic monophosphate by bovine adrenal extracts.

Authors:  J Linkola; F Fyhrquist; T H Weber; L Puutula
Journal:  Biochem J       Date:  1977-09-15       Impact factor: 3.857

2.  Urinary excretion of cyclic adenosine 3',5'-monophosphate and cyclic guanosine 3',5'-monophosphate in malignancy.

Authors:  C Gennari; G Francini; M Galli; F Lore
Journal:  J Clin Pathol       Date:  1978-08       Impact factor: 3.411

3.  The control of growth of mouse mastocytoma cells by N6,O2'-dibutyryladenosine cyclic 3',5'-monophosphate.

Authors:  A Knightbridge; R K Ralph
Journal:  Mol Cell Biochem       Date:  1981-02-11       Impact factor: 3.396

4.  The content and metabolism of cyclic adenosine 3', 5'-monophosphate and cyclic guanosine 3', 5'-monophosphate in adenocarcinoma of the human colon.

Authors:  F R DeRubertis; R Chayoth; J B Field
Journal:  J Clin Invest       Date:  1976-03       Impact factor: 14.808

5.  Prostaglandin E2 and cyclic AMP levels in human breast tumors.

Authors:  N Feller; T Malachi; I Halbrecht
Journal:  J Cancer Res Clin Oncol       Date:  1979-04-12       Impact factor: 4.553

6.  Prostaglandin E2 and cyclic AMP in tumor and plasma of breast cancer patients.

Authors:  T Malachi; C Chaimoff; N Feller; I Halbrecht
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

7.  Acetylsalicylic acid (ASA) protects the prostaglandin-cAMP-system of human hypernephroma cells against irradiation-induced alterations.

Authors:  S R Li; Q Yang; E Wandl; W Pirker; I Virgolini
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.